Skip to main content
OpenTrials
Completed

NCT Number: NCT03884413

FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France

FErtility, PrEgnancy, contRaceptIon after breast Cancer in France

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–43 year

Sex eligibility

Female

Study type

Observational

Primary location

Seintinelles.Com

Paris, France

About this study

Breast cancer is the most common cancer among women. With the increase of the survival rates, a growing attention is paid to the side effects of the treatments, particularly chemotherapy-induced infertility.

The FEERIC study will give insights into spontaneous fertility outcomes following breast cancer in comparison with a control cohort and will provide data to help patients counselling towards spontaneous fertility rates following breast cancer. It will also provide data on contraceptive prevalence and unintended pregnancy rates in French breast cancer survivors. Reasons for unmet need for family planning will be deciphered, in order to point out pitfalls (lack of patient's information or orientation/ignorance of contraception methods available/topic insufficiently or not discussed with the physician/ lack of family planning offer etc…); and target the appropriate actions to lead (oncologist and oncology nurses education/ dedicated consultations in breast cancer centers/etc…).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • females aged from 18 to 43 at inclusion
  • previous diagnosis of breast cancer and time from diagnosis comprised between one and five years or women free from breast cancer or other malignancy (healthy volunteers) .

Exclusion criteria

  • hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy
  • healthy volonteer with history of malignant disease.

Treatment and study plan

questionnaires

Other

Longitudinal observational study. Collection of health data using self-administered questionnaires online.

Primary outcomes

  1. Spontaneous pregnancies between cases and controls

    Time frame: 3 years

    Odds ratio between the spontaneous pregnancies between cases and controls, for women with a desire to become pregnant and trying to get pregnant.

Secondary outcomes

  1. Time to spontaneous pregnancy

    Time frame: 3 years

    Time to spontaneous pregnancy after breast cancer diagnosis, for women with a desire to become pregnant and trying to get pregnant.

  2. Contraceptive prevalence

    Time frame: 3 years

    Contraceptive use, defined as the percentage of women reporting use of a contraceptive method.

  3. Rate of women considered with risk of unintended pregnancy

    Time frame: 3 years

    An unwanted pregnancy is defined as unwanted at the time of conception. Women are classified as at risk of unwanted pregnancy if they report having had unprotected sex without a desire to become pregnant in the previous four months.

  4. Percentage of live births obtained by medically assisted procreation procedures

    Time frame: 3 years

    Percentages live births obtained by ARTs procédures, that include in vitro fertilization (IVF) and embryo transfer (ET), intracytoplasmic sperm injection (ICSI) and ovarian stimulation with exogenous gonadotropins.

Sponsors and collaborators

Lead sponsor

Institut Curie

Other

Collaborators

  • seintinelles network

Registry information

Official study title

FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France: the FEERIC Study

Acronym: FEERIC

Important dates

Study start
2018
Primary completion
2021
Study completion
2022
First posted
Mar 21, 2019
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.